Oct 23, 2023
Source:
APAAACI 2023 International Conference, Singapore
Bradykinin B2 receptor antagonist deucrictibant immediate-release capsule for treatment of HAE attacks: Phase 2
Presentation 1.3 MB
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 4.4 MB
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks
Presentation 2.7 MB
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Presentation 395.9 KB
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 484.3 KB
Sep 02, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 1 MB
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 1 MB
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: CHAPTER-1 phase 2 trial design
Poster 319.2 KB
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms
Poster 1 MB
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Poster 1.8 MB
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
Poster 1.1 MB
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
Poster 700.6 KB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
Presentation 1.1 MB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
Poster 1.1 MB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
Presentation 870.7 KB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
Poster 1.6 MB
May 05, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 850.4 KB
Mar 18, 2023
Source:
2023 HAEi Regional Conference APAC, Bangkok
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presentation 920.2 KB
Feb 26, 2023
Source:
2023 AAAAI Annual Meeting, San Antonio, TX
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 1.1 MB
Presentation 6.3 MB
Nov 13, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Poster 937.4 KB
Nov 12, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Poster 818.4 KB
Oct 07, 2022
Source:
2022 HAEi Global Leadership Workshop, Frankfurt
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Poster 920.1 KB
Sep 16, 2022
Source:
Bradykinin Symposium 2022, Berlin
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Presentation 926.6 KB
Jun 07, 2022
Source:
Satellite Symposium Kinin 2022
Tailored drug development for patients living with HAE
Presentation 1.6 MB
Mar 22, 2022
Source:
International Immunopharmacology
In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development
Jul 10, 2021
Source:
EAACI Annual Congress 2021, Virtual
Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAE
Poster 535.7 KB
Jun 04, 2021
Source:
12th C1-inhibitor Deficiency and Angioedema Workshop, Virtual
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Presentation 4.9 MB
Video 38.7 MB
Feb 26, 2021
Source:
2021 AAAAI Annual Meeting, Virtual
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Poster 1.9 MB
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Poster 664.1 KB
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Poster 746.5 KB
Jul 30, 2020
Source:
Frontiers in Pharmacology
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Publication 1.7 MB
Apr 09, 2020
Source:
2020 AAAAI Annual Meeting, Virtual
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model
Poster 931.5 KB